Core B: University of Kentucky Alzheimer's Disease Core Center

项目摘要/摘要：临床核心 英国-ADRC的临床核心保持着一个特征良好的、以社区为基础的队列，专注于 正常衰老和早期过渡性疾病状态，并纵向跟踪个体，直到脑部尸检。 我们维持对所有受试者的强制性尸检要求(少数族裔网关除外 促进尸检但不要求尸检的诊所)，允许在临床- 病理学相关研究，以及早期临床前和痴呆前疾病状态的定义。这些 努力一直是我们认识到社区获得性痴呆症的异质性的动力， 包括对晚期、部分、VCID领域的主要贡献，以及这些病理变化的作用 州与传统的AD、LBD和FTLD疾病州一起玩。我们工作的一个主要重点是 也一直在定义早期临床过渡，涉及这些疾病状态的相互作用， 老年多病因痴呆综合征的广泛探索。为了进一步推动这种进步， 英国-ADRC临床核心强调深层次的临床、生物标记物、遗传和尸检表型 多病因痴呆症高危老年人的不同队列。反兴奋剂领域的主要举措 从正常到晚年多病因痴呆的模仿和过渡已经做好了准备，将继续推动 在诊断和转化性介入发现领域的领域前沿。我们已经介绍了 我们在扩大生前生物标记物研究方面采取了令人兴奋的新举措，允许进行更深入的临床研究 当我们致力于多病因痴呆症的翻译发现时，我们的参与者的表型。这个 英国-ADRC将继续通过我们提出的具体目标以动态的方式不断发展。 目标1：维持和纵向描述纳入认知正常受试者的中央纵向队列 为了促进我们对临床前疾病的理解和早期认知向多病因MCI& 痴呆症。 目标2：维护和扩大我们成功的少数族裔网关诊所，以保持和发展我们的(显著) 人口少数群体参与率高于平均水平。 目标3：进一步发展和维护基础设施，通过以下方式支持转化性治疗开发 所有临床试验阶段，支持NIH、ADCS、ACTC倡议、行业赞助的药物试验，以及 由调查员发起的项目。 目标4：促进对研究参与者和家庭的教育和支持，以确保我们的努力 在新的预防研究和已有疾病的治疗方面都具有临床意义 总体而言，临床核心将继续提供基础设施和环境，将继续 帮助我们成功地推进多学科、创新的广告研究，支持我们的中心主题 从正常到老年多病因性痴呆的转变。

Project Summary/Abstract: Clinical Core The Clinical Core of the UK-ADRC maintains a well-characterized, community-based cohort focused on normal aging and early transitional disease states and follows individuals longitudinally until brain autopsy. We maintain a mandatory autopsy requirement for all subjects (with the exception of our Minority Gateway Clinic, where autopsy is promoted but not required), allowing major contributions in the area of clinical- pathological correlative studies, and definition of early preclinical and pre-dementia disease states. These efforts have been a driving force in our recognition of the heterogeneity of community-acquired dementia, including major contributions to the field in regard to LATE, PART, VCID, and the role these pathologic states play in conjunction with traditional AD, LBD, and FTLD disease states. A major focus of our work has also been on defining early clinical transitions involving the interplay of these disease states that has driven the widespread exploration of late-life multi-etiology dementia syndromes. To further such advances, the UK-ADRC Clinical Core emphasizes deep clinical, biomarker, genetic, and post-mortem phenotyping of a diverse cohort of elderly subjects at high risk for multi-etiology dementia. Major initiatives in the area of AD mimics and transitions from normal to late-life multi-etiology dementia are well-poised to continue to move the field forward in the areas of both diagnosis and translational interventional discoveries. We have introduced exciting new initiatives in our expansion of antemortem biomarker research allowing an even deeper clinical phenotyping of our participants as we work towards translational discoveries for multi-etiology dementia. The UK-ADRC will continue to constantly evolve in dynamic ways through our proposed specific aims. Aim 1: Maintain & longitudinally characterize a central longitudinal cohort enrolling cognitively normal subjects to facilitate our understanding of preclinical disease and early cognitive transitions to multi-etiology MCI & dementia. Aim 2: Maintain and expand our successful Minority Gateway Clinics to maintain and grow our (significantly) above-parity for population minority engagement. Aim 3: Further develop and maintain an infrastructure to support translational therapeutic development through all clinical trial phases in support of NIH, ADCS, ACTC initiatives, industry-sponsored drug trials, and investigator-initiated projects. Aim 4: Foster education and support of research participants and families to ensure that our efforts are clinically meaningful, both in novel prevention studies as well as treatment in established disease Overall, the Clinical Core will continue to provide an infrastructure and environment that will continue to contribute to our success in advancing multidisciplinary, innovative AD research supporting our center theme of Transitions from Normal to Late-Life Multi-Etiology Dementia.